Crestor, a cholesterol lowering statin, does not appear to reduce deaths in heart failure patients, according to a new study published in the New England Journal of Medicine. The results of the 5,000 person CORONA study are a big blow to AtraZeneca, which had hoped to market Crestor as the first statin to show clear benefits in treating chronic heart conditions in the elderly.
Crestor was approved by the Food & Drug Administration (FDA) in 2003. It is a member of a drug class called statins, which lower so-called “bad” cholesterol, otherwise known as LDL cholesterol. Although Crestor’s cholesterol lowering ability was already established, the CORONA study was the first to explore whether Crestor improved patient outcomes in heart failure patients.

